UroGen Pharma Ltd (NASDAQ: URGN) kicked off on Tuesday, down -3.01% from the previous trading day, before settling in for the closing price of $9.96. Over the past 52 weeks, URGN has traded in a range of $9.03-$20.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13165.79% over the last five years. While this was happening, its average annual earnings per share was recorded 2.84%. With a float of $38.22 million, this company’s outstanding shares have now reached $42.23 million.
The firm has a total of 235 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.18%, operating margin of -107.06%, and the pretax margin is -137.22%.
UroGen Pharma Ltd (URGN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of UroGen Pharma Ltd is 17.09%, while institutional ownership is 80.29%. The most recent insider transaction that took place on Jan 31 ’25, was worth 50,698. In this transaction Chief Medical Officer of this company sold 4,551 shares at a rate of $11.14, taking the stock ownership to the 145,666 shares. Before that another transaction happened on Jan 31 ’25, when Company’s General Counsel sold 7,379 for $11.14, making the entire transaction worth $82,202. This insider now owns 26,468 shares in total.
UroGen Pharma Ltd (URGN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.84% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Take a look at UroGen Pharma Ltd’s (URGN) current performance indicators. Last quarter, stock had a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.22, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Analysing the last 5-days average volume posted by the [UroGen Pharma Ltd, URGN], we can find that recorded value of 0.52 million was better than the volume posted last year of 0.4 million. As of the previous 9 days, the stock’s Stochastic %D was 11.84%. Additionally, its Average True Range was 0.68.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 15.35%, which indicates a significant increase from 4.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.83% in the past 14 days, which was higher than the 45.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.68, while its 200-day Moving Average is $12.60. Now, the first resistance to watch is $10.26. This is followed by the second major resistance level at $10.85. The third major resistance level sits at $11.22. If the price goes on to break the first support level at $9.30, it is likely to go to the next support level at $8.93. Should the price break the second support level, the third support level stands at $8.34.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
The company with the Market Capitalisation of 445.27 million has total of 46,094K Shares Outstanding. Its annual sales at the moment are 90,400 K in contrast with the sum of -126,870 K annual income. Company’s last quarter sales were recorded 24,570 K and last quarter income was -37,510 K.
